The Secret is the Secretions
Stem cells hold great promise, but is it the cells we really need?
Nicolas Sohl |
Ophthalmology is full of advances, but sometimes the field is very conservative. Look at the extended-release drug delivery systems that have made it to market: Vitrasert, Ozurdex, Retisert, Iluvien. New drug delivery technology, but really old drugs (ganciclovir, dexamethasone, and fluocinolone acetonide). I think it’s clear that the use of steroids for the treatment of retinal disease will diminish – their drawbacks and side-effects are well-known, and there’s (hopefully) better therapeutic approaches on the horizon.
Many companies are focusing on cell therapies to treat retinal diseases. They look like an attractive option; they’ve been heralded as being able to “regenerate” or “rebuild” the retina. There are a number of companies that are currently developing and even trialing intravitreal stem cells clinically for retinopathies, in particular for retinitis pigmentosa, Stargardt disease and AMD. If they can deliver on their promise, that’s wonderful. But there are aspects of this approach that still need to be resolved.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine